{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:18:42Z","timestamp":1792685922252,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":2150,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s13311-017-0573-4","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T09:31:17Z","timestamp":1511343077000},"page":"874-887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"title":["Cladribine to Treat Relapsing Forms of Multiple Sclerosis"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-1700","authenticated-orcid":false,"given":"Gavin","family":"Giovannoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1007\/s13311-017-0573-4_bib1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood.V62.4.737.737","article-title":"Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes","volume":"62","author":"Carson","year":"1983","journal-title":"Blood"},{"issue":"6","key":"10.1007\/s13311-017-0573-4_bib2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1586\/14737175.5.6.721","article-title":"Cladribine for multiple sclerosis: review and current status","volume":"5","author":"Sipe","year":"2005","journal-title":"Expert Rev. Neurother."},{"issue":"8914","key":"10.1007\/s13311-017-0573-4_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(94)91046-4","article-title":"Cladribine in treatment of chronic progressive multiple sclerosis","volume":"344","author":"Sipe","year":"1994","journal-title":"Lancet."},{"issue":"8825","key":"10.1007\/s13311-017-0573-4_bib4","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/0140-6736(92)92826-2","article-title":"Cladribine (2-chlorodeoxyadenosine)","volume":"340","author":"Beutler","year":"1992","journal-title":"Lancet."},{"issue":"5","key":"10.1007\/s13311-017-0573-4_bib5","first-page":"1145","article-title":"Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial","volume":"54","author":"Rice","year":"2000","journal-title":"Cladribine MRI Study Group. Neurology."},{"issue":"1 Suppl. 1","key":"10.1007\/s13311-017-0573-4_bib6","first-page":"45","article-title":"Treatment of multiple sclerosis and other autoimmune diseases with cladribine","volume":"33","author":"Beutler","year":"1996","journal-title":"Semin. Hematol."},{"issue":"1","key":"10.1007\/s13311-017-0573-4_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1525-1381.1999.09115.x","article-title":"A double-blind, placebo-controlled, randomized trial of cladribine in relpaasing-remitting multiple sclerosis","volume":"111","author":"Romine","year":"1999","journal-title":"Proc. Assoc. Am. Physicians."},{"issue":"1","key":"10.1007\/s13311-017-0573-4_bib8","first-page":"93","article-title":"Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis","volume":"7","author":"Janiec","year":"2001","journal-title":"Med. Sci. Monit."},{"issue":"3","key":"10.1007\/s13311-017-0573-4_bib9","first-page":"225","article-title":"Effect of cladribine treatment on beta-2 microglobulin and soluble intercellular adhesion molecule 1 (ICAM-1) in patients with multiple sclerosis","volume":"60","author":"Niezgoda","year":"2001","journal-title":"Folia Morphol."},{"issue":"6","key":"10.1007\/s13311-017-0573-4_bib10","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1600-0404.2004.00259.x","article-title":"Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine","volume":"109","author":"Bartosik-Psujek","year":"2004","journal-title":"Acta Neurol. Scand."},{"issue":"3","key":"10.1007\/s13311-017-0573-4_bib11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1468-1331.2008.02433.x","article-title":"Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis","volume":"16","author":"Kopadze","year":"2009","journal-title":"Eur. J. Neurol."},{"issue":"5","key":"10.1007\/s13311-017-0573-4_bib12","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1007\/s13311-017-0573-4_bib13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.V81.3.597.597","article-title":"Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine","volume":"81","author":"Kawasaki","year":"1993","journal-title":"Blood."},{"issue":"11","key":"10.1007\/s13311-017-0573-4_bib14","doi-asserted-by":"crossref","first-page":"R130","DOI":"10.1186\/gb-2009-10-11-r130","article-title":"BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources","volume":"10","author":"Wu","year":"2009","journal-title":"Genome Biol."},{"issue":"6","key":"10.1007\/s13311-017-0573-4_bib15","doi-asserted-by":"crossref","first-page":"430","DOI":"10.7326\/0003-4819-121-6-199409150-00006","article-title":"2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis","volume":"121","author":"Saven","year":"1994","journal-title":"Ann. Intern. Med."},{"issue":"24 Pt 1","key":"10.1007\/s13311-017-0573-4_bib16","first-page":"6923","article-title":"Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells","volume":"49","author":"Griffig","year":"1989","journal-title":"Cancer Res."},{"key":"10.1007\/s13311-017-0573-4_bib17","unstructured":"Laugel B, Challier J, Siegfried C, Chvatchko Y, Salvat C, Weissert R. The mechanism of action behind the lymphocyte-depleting and immunomodulatory effects of cladribine. Abstract P01. 108. In: 61st Annual Meeting of the American Academy of Neurology. (2009)."},{"issue":"1","key":"10.1007\/s13311-017-0573-4_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1517\/17425250903393745","article-title":"The cladribine conundrum: deciphering the drug's mechanism of action","volume":"6","author":"Hentosh","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"6","key":"10.1007\/s13311-017-0573-4_bib19","doi-asserted-by":"crossref","first-page":"e0129182","DOI":"10.1371\/journal.pone.0129182","article-title":"Cladribine exposure results in a sustained modulation of the cytokine response in human peripheral blood mononuclear cells","volume":"10","author":"Korsen","year":"2015","journal-title":"Plos One."},{"issue":"7","key":"10.1007\/s13311-017-0573-4_bib20","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.1996.14.7.2160","article-title":"Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia","volume":"14","author":"Juliusson","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1007\/s13311-017-0573-4_bib21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1532\/IJH97.04077","article-title":"Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study","volume":"80","author":"Ogura","year":"2004","journal-title":"Int. J. Hematol."},{"issue":"5","key":"10.1007\/s13311-017-0573-4_bib22","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3109\/03009749709065702","article-title":"The safety profile of low-dose cladribine in refractory rheumatoid arthritis","volume":"26","author":"Schirmer","year":"1997","journal-title":"Scand. J. Rheumatol."},{"issue":"2","key":"10.1007\/s13311-017-0573-4_bib23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/1529-0131(199802)41:2<335::AID-ART18>3.0.CO;2-O","article-title":"A pilot study of 2-chloro-2\u2032-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis","volume":"41","author":"Davis","year":"1998","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1007\/s13311-017-0573-4_bib24","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1073\/pnas.93.4.1716","article-title":"The treatment of chronic progressive multiple sclerosis with cladribine","volume":"93","author":"Beutler","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1007\/s13311-017-0573-4_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/ern.10.12","article-title":"Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis","volume":"10","author":"Sipe","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"10.1007\/s13311-017-0573-4_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2210-5-4","article-title":"Application of population pharmacokinetics to cladribine","volume":"5","author":"Lindemalm","year":"2005","journal-title":"BMC Pharmacol."},{"issue":"6","key":"10.1007\/s13311-017-0573-4_bib27","first-page":"536","article-title":"A limited sampling strategy for estimation of the cladribine plasma area under the concentration versus time curve after intermittent i.v. infusion, s.c. injection, and oral administration. Cancer Chemother","volume":"38","author":"Liliemark","year":"1996","journal-title":"Pharmacol."},{"issue":"2","key":"10.1007\/s13311-017-0573-4_bib28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2165\/00003088-199732020-00003","article-title":"The clinical pharmacokinetics of cladribine","volume":"32","author":"Liliemark","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"10.1007\/s13311-017-0573-4_bib29","article-title":"Preferential effects of cladribine on lymphocyte subpopulations","volume":"14","author":"Guarnaccia","year":"2008","journal-title":"Mult. Scler."},{"key":"10.1007\/s13311-017-0573-4_bib30","unstructured":"Soelberg-Sorensen P, Comi G, Cook S, et al. Effects of cladribine tablets on haematological profiles in patients with relapsing-remitting multiple sclerosis (RRMS) in the 96 week, phase III, double-blind, placebo-controlled CLARITY study. Meeting Abstract. In: Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Dusseldorf, Germany. 9\u201312 (2009)."},{"issue":"5","key":"10.1007\/s13311-017-0573-4_bib31","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3109\/07357909309011674","article-title":"2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia","volume":"11","author":"Saven","year":"1993","journal-title":"Cancer Invest."},{"issue":"11","key":"10.1007\/s13311-017-0573-4_bib32","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1185\/030079907X233142","article-title":"The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation","volume":"23","author":"Leist","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1007\/s13311-017-0573-4_bib33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1007\/s13311-017-0573-4_bib34","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.53.3.448","article-title":"The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis","volume":"53","author":"Fazekas","year":"1999","journal-title":"Neurology."},{"issue":"1","key":"10.1007\/s13311-017-0573-4_bib35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.msard.2011.08.006","article-title":"Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study","volume":"1","author":"Rammohan","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1007\/s13311-017-0573-4_bib36","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/S0022-510X(09)70458-7","article-title":"FP36-WE-03 MRI outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study","volume":"285","author":"Comi","year":"2009","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1007\/s13311-017-0573-4_bib37","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s00415-012-6775-0","article-title":"MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study","volume":"260","author":"Comi","year":"2013","journal-title":"J. Neurol."},{"issue":"4","key":"10.1007\/s13311-017-0573-4_bib38","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","article-title":"Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis","volume":"10","author":"Giovannoni","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1007\/s13311-017-0573-4_bib39","article-title":"Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets","author":"De Stefano","year":"2017","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1007\/s13311-017-0573-4_bib40","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1352458510391344","article-title":"Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study","volume":"17","author":"Cook","year":"2011","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1007\/s13311-017-0573-4_bib41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/11593310-000000000-00000","article-title":"Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study","volume":"32","author":"Ali","year":"2012","journal-title":"Clin. Drug Investig."},{"key":"10.1007\/s13311-017-0573-4_bib42","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study","author":"Giovannoni","year":"2017","journal-title":"Mult. Scler."},{"issue":"16 Suppl.","key":"10.1007\/s13311-017-0573-4_bib43","article-title":"Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg\/kg in CLARITY and CLARITY Extension (P5.379)","volume":"88","author":"Soelberg-Sorensen","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"10.1007\/s13311-017-0573-4_bib44","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurol."},{"issue":"7 Suppl","key":"10.1007\/s13311-017-0573-4_bib45","first-page":"P07.119","article-title":"Safety and efficacy of oral cladribine in patients with relapsing-remitting multiple sclerosis: results from the 96 week phase IIIb extension trial to the CLARITY study (P07.119)","volume":"80","author":"Giovannoni","year":"2013","journal-title":"Neurology"},{"key":"10.1007\/s13311-017-0573-4_bib46","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1016\/S0022-510X(09)70788-9","article-title":"PO10-TU-39 Safety and tolerability of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study","volume":"285","author":"Cook","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"10.1007\/s13311-017-0573-4_bib47","first-page":"S454","article-title":"Mitigating severe lymphopenia: post hoc analysis of data from the 96-week CLARITY study","volume":"17","author":"Giovannoni","year":"2011","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1007\/s13311-017-0573-4_bib48","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1212\/NXI.0000000000000360","article-title":"Both cladribine and alemtuzumab may effect MS via B-cell depletion","volume":"4","author":"Baker","year":"2017","journal-title":"Neurology Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1007\/s13311-017-0573-4_bib49","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1212\/NXI.0000000000000158","article-title":"No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine","volume":"2","author":"Pakpoor","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"10.1007\/s13311-017-0573-4_bib50","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1200\/JCO.1999.17.8.2454","article-title":"Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias","volume":"17","author":"Cheson","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1007\/s13311-017-0573-4_bib51","first-page":"S144","article-title":"Evaluation of the long-term safety of cladribine tablets in multiple sclerosis: design of PREMIERE, a prospective, observational 8-year safety registry","volume":"257","author":"Miret","year":"2010","journal-title":"J. Neurol."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-017-0573-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-017-0573-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923014095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923014095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-017-0573-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:01:55Z","timestamp":1761807715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923014095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1878747923014095"],"URL":"https:\/\/doi.org\/10.1007\/s13311-017-0573-4","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cladribine to Treat Relapsing Forms of Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-017-0573-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}